H. Sorbye, M. Mauer, T. Gruenberger, B. Glimelius, G. J. Poston, P. M. Schlag, P. Rougier, W. O. Bechstein, J. N. Primrose, E. T. Walpole, M. Finch-Jones, D. Jaeck, D. Miza, R. W. Parks, L. Collette, E. V. Cutsem, W. Scheithauer, M. P. Lutz and B. Nordlinger, “Predictive Factors for the Benefit of Perioperative FOLFOX for Resectable Liver Metastasis in Colorectal Cancer Patients (EORTC Intergroup Trial 40983),” Annals of Surgery, Vol. 255, No. 3, 2012, pp. 534-539. doi:10.1097/SLA.0b013e3182456aa2

has been cited by the following article:

• TITLE: Strategies for Synchronous and Multiple Metastatic Liver Tumors Designed from Epithelial-Mesenchymal Transition Concept

  AUTHORS: Shinji Osada, Hisashi Imai, Yoshiyuki Sasaki, Kazuhiro Yoshida

  KEYWORDS: Colorectal Cancer; Surgical Indication; Synchronous and Multiple Liver Metastasis; Epithelial-Mesenchymal Transition (EMT)

  JOURNAL NAME: Journal of Cancer Therapy, Vol.3 No.3, June 20, 2012

  ABSTRACT: At some point in the natural course of colorectal cancer up to 50% of patients will develop metastasis to the liver and it is one of the most critical effects for patient prognosis. The incidence of synchronous liver metastasis has been detected at around 20% - 25%, but the optimal timing of surgical resection remains controversial. Neoadjuvant chemotherapy has also been found to be beneficial not only for initially unresectable but also resectable synchronous metastases. Then, traditional surgical strategies of hepatic resection in accordance with past chemotherapeutic regimens have been used decreasingly over the past several years. This review will primarily discuss treatments in association with the recent developed chemotherapeutic regimens and surgical procedure from the clinical data and the concept for epithetlial-mesenchymal transition, which has recently been studied to elucidate mechanisms of the liver metastatic process.